TikoMed will speak at Boston Biotech Cell and Gene Therapy CEO meeting.

September, 25, mon,

Time:


TikoMed originated its development in overcoming the attacks of the innate immune system following islet cell transplantation into the bloodstream. The effects of TikoMeds IBSOLVMIR compound has been well documented in vitro and in vivo and a Phase 2 study. Adam Bruce, CEO of TikoMed is honored to have been asked to present at the meeting and will be very happy to present TikoMed’s path forward to make cell therapies more efficient.

The conference is the perfect opportunity to meet and discuss opportunities in the field at the highest level of executives.

http://bbbiotechconference.com/conference-details.php?id=58

Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing and delivery challenges. Healthcare investors and leading researchers also participate.

Keynote Speakers Confirmed:
George Church, Professor of Genetics, Harvard Medical School
J. Craig VenterCo-Founder & Executive Chairman, Human Longevity
Michael WestCo-CEO, BioTime

Speakers and Co-Hosts Include:
Adam BruceCEO, Founder & Board Member, TikoMed; Nick ColangeloCEO, Vericel; John CoxCEO, Bioverativ; Olivier DanosCSO, Regenxbio; John DawsonCEO, Oxford Biomedica; Richard GaynorPresident & CEO, Neon Therapeutics; David GraingerPartner, Medicxi Ventures; Adam GridleyPresident & CEO, Histogenics; Sven KiliVP, Gene Therapy Development Head, GlaxoSmithKline; Gregory LaRosaCSO & SVP, Rare Disease Research,Pfizer; Christopher LooseCo-Founder & CSO, Frequency Therapeutics; Geoff MacKayPresident & CEO, AvroBio; James NobleCEO, Adaptimmune; Amber SalzmanPresident & CEO, Adverum; Alvin ShihCEO, Enzyvant; Sue WasherPresident & CEO, AGTC; Michael WestCo-CEO, BioTime; J. Craig VenterCo-Founder & Executive Chairman, Human Longevity; Luhan Yang, President, CSO & Co-Founder, Egenesis Bio